David Voyticky joins Genesis Biopharma board
This article was originally published in Scrip
David Voyticky has joined the board of Genesis Biopharma, a biotech developing targeted cancer therapies, bringing the total number of board member to six. Mr Voyticky is currently president of Miller Energy Resources, an oil and gas exploration company, and previously served as vice-president of Goldman Sachs.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.